Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Common Equity: 2018-2020

Historic Common Equity for Black Diamond Therapeutics (BDTX) over the last 3 years, with Dec 2020 value amounting to $307.8 million.

  • Black Diamond Therapeutics' Common Equity fell 33.11% to $218.9 million in Q3 2021 from the same period last year, while for Sep 2021 it was $218.9 million, marking a year-over-year decrease of 33.11%. This contributed to the annual value of $307.8 million for FY2020, which is 752.62% up from last year.
  • Per Black Diamond Therapeutics' latest filing, its Common Equity stood at $307.8 million for FY2020, which was up 752.62% from -$47.2 million recorded in FY2019.
  • Over the past 5 years, Black Diamond Therapeutics' Common Equity peaked at $307.8 million during FY2020, and registered a low of -$47.2 million during FY2019.
  • For the 3-year period, Black Diamond Therapeutics' Common Equity averaged around $81.7 million, with its median value being -$15.5 million (2018).
  • In the last 5 years, Black Diamond Therapeutics' Common Equity slumped by 203.42% in 2019 and then surged by 752.62% in 2020.
  • Black Diamond Therapeutics' Common Equity (Yearly) stood at -$15.5 million in 2018, then tumbled by 203.42% to -$47.2 million in 2019, then soared by 752.62% to $307.8 million in 2020.